Literature DB >> 23504321

Targeting of heparanase-modified syndecan-1 by prosecretory mitogen lacritin requires conserved core GAGAL plus heparan and chondroitin sulfate as a novel hybrid binding site that enhances selectivity.

Yinghui Zhang1, Ningning Wang, Ronald W Raab, Robert L McKown, Jacob A Irwin, Inchan Kwon, Toin H van Kuppevelt, Gordon W Laurie.   

Abstract

Cell surface heparan sulfate (HS) proteoglycans shape organogenesis and homeostasis by capture and release of morphogens through mechanisms largely thought to exclude the core protein domain. Nevertheless, heparanase deglycanation of the N-terminal HS-rich domain of syndecan-1 (SDC1), but not SDC2 or -4, is a prerequisite for binding of the prosecretory mitogen lacritin (Ma, P., Beck, S. L., Raab, R. W., McKown, R. L., Coffman, G. L., Utani, A., Chirico, W. J., Rapraeger, A. C., and Laurie, G. W. (2006) Heparanase deglycanation of syndecan-1 is required for binding of the epithelial-restricted prosecretory mitogen lacritin. J. Cell Biol. 174, 1097-1106). We now report that the conserved and hydrophobic GAGAL domain in SDC1, adjacent to predicted HS substitution sites, is necessary to ligate and substantially enhance the α-helicity of the amphipathic C terminus of lacritin. Swapping out GAGAL for GADED in SDC2 or for GDLDD in SDC4 (both less hydrophobic) abrogated binding. HS and chondroitin sulfate are also essential. Both are detected in the N terminus, and when incubated with antibodies HS4C3 (anti-HS) or IO3H10 (anti-chondroitin sulfate), binding was absent, as occurred when all three N-terminal glycosaminoglycan substitution sites were mutated to alanine or when cells were treated with 4-methylumbelliferyl-β-d-xylopyranoside or chlorate to suppress glycosaminoglycan substitution or sulfation, respectively. SDC1 interacts with the hydrophobic face of lacritin via Leu-108/Leu-109/Phe-112 as well as with Glu-103/Lys-107 and Lys-111 of the largely cationic face. Carving a hybrid hydrophobic/electrostatic docking site out of SDC1 in a manner dependent on endogenous heparanase is a dynamic process appropriate for subtle or broad epithelial regulation in morphogenesis, health, and disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23504321      PMCID: PMC3636894          DOI: 10.1074/jbc.M112.422717

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  61 in total

1.  Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1.

Authors:  Augen A Pioszak; Naomi R Parker; Kelly Suino-Powell; H Eric Xu
Journal:  J Biol Chem       Date:  2008-09-17       Impact factor: 5.157

2.  Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor.

Authors:  Christoph Parthier; Martin Kleinschmidt; Piotr Neumann; Rainer Rudolph; Susanne Manhart; Dagmar Schlenzig; Jörg Fanghänel; Jens-Ulrich Rahfeld; Hans-Ulrich Demuth; Milton T Stubbs
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-21       Impact factor: 11.205

3.  Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain.

Authors:  Steffen Runge; Henning Thøgersen; Kjeld Madsen; Jesper Lau; Rainer Rudolph
Journal:  J Biol Chem       Date:  2008-02-20       Impact factor: 5.157

4.  Identification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomics.

Authors:  Lei Zhou; Roger W Beuerman; Choi Mun Chan; Shao Zhen Zhao; Xiao Rong Li; He Yang; Louis Tong; Shouping Liu; Michael E Stern; Donald Tan
Journal:  J Proteome Res       Date:  2009-11       Impact factor: 4.466

5.  Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding.

Authors:  Mariana I Capurro; Ping Xu; Wen Shi; Fuchuan Li; Angela Jia; Jorge Filmus
Journal:  Dev Cell       Date:  2008-05       Impact factor: 12.270

6.  Heparan sulfate biosynthesis enzymes EXT1 and EXT2 affect NDST1 expression and heparan sulfate sulfation.

Authors:  Jenny Presto; Maria Thuveson; Pernilla Carlsson; Marta Busse; Maria Wilén; Inger Eriksson; Marion Kusche-Gullberg; Lena Kjellén
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-12       Impact factor: 11.205

7.  The survival-promoting peptide Y-P30 enhances binding of pleiotrophin to syndecan-2 and -3 and supports its neuritogenic activity.

Authors:  Peter Landgraf; Petra Wahle; Hans-Christian Pape; Eckart D Gundelfinger; Michael R Kreutz
Journal:  J Biol Chem       Date:  2008-07-03       Impact factor: 5.157

8.  The core protein of glypican Dally-like determines its biphasic activity in wingless morphogen signaling.

Authors:  Dong Yan; Yihui Wu; Ying Feng; Sheng-Cai Lin; Xinhua Lin
Journal:  Dev Cell       Date:  2009-10       Impact factor: 12.270

Review 9.  Lacritin and other new proteins of the lacrimal functional unit.

Authors:  Robert L McKown; Ningning Wang; Ronald W Raab; Roy Karnati; Yinghui Zhang; Patricia B Williams; Gordon W Laurie
Journal:  Exp Eye Res       Date:  2008-09-18       Impact factor: 3.467

10.  Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformation-selective peptides.

Authors:  Augen A Pioszak; Naomi R Parker; Thomas J Gardella; H Eric Xu
Journal:  J Biol Chem       Date:  2009-08-12       Impact factor: 5.157

View more
  17 in total

Review 1.  Lacritin and other autophagy associated proteins in ocular surface health.

Authors:  Roy Karnati; Venu Talla; Katherine Peterson; Gordon W Laurie
Journal:  Exp Eye Res       Date:  2015-08-25       Impact factor: 3.467

Review 2.  Lacritin and the tear proteome as natural replacement therapy for dry eye.

Authors:  Roy Karnati; Diane E Laurie; Gordon W Laurie
Journal:  Exp Eye Res       Date:  2013-06-12       Impact factor: 3.467

Review 3.  TFOS DEWS II Tear Film Report.

Authors:  Mark D P Willcox; Pablo Argüeso; Georgi A Georgiev; Juha M Holopainen; Gordon W Laurie; Tom J Millar; Eric B Papas; Jannick P Rolland; Tannin A Schmidt; Ulrike Stahl; Tatiana Suarez; Lakshman N Subbaraman; Omür Ö Uçakhan; Lyndon Jones
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

4.  A cleavage-potentiated fragment of tear lacritin is bactericidal.

Authors:  Robert L McKown; Erin V Coleman Frazier; Kaneil K Zadrozny; Andrea M Deleault; Ronald W Raab; Denise S Ryan; Rose K Sia; Jae K Lee; Gordon W Laurie
Journal:  J Biol Chem       Date:  2014-06-18       Impact factor: 5.157

5.  A Proteoglycan-Like Molecule Offers Insights Into Ground Substance Changes During Holothurian Intestinal Regeneration.

Authors:  Gabriel E Vázquez-Vélez; José F Rodríguez-Molina; Mónica C Quiñones-Frías; María Pagán; José E García-Arrarás
Journal:  J Histochem Cytochem       Date:  2016-04-28       Impact factor: 2.479

Review 6.  The Lacritin-Syndecan-1-Heparanase Axis in Dry Eye Disease.

Authors:  Karina Dias-Teixeira; Xavier Horton; Robert McKown; Jeffrey Romano; Gordon W Laurie
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

7.  A thermo-responsive protein treatment for dry eyes.

Authors:  Wan Wang; Aarti Jashnani; Suhaas R Aluri; Joshua A Gustafson; Pang-Yu Hsueh; Frances Yarber; Robert L McKown; Gordon W Laurie; Sarah F Hamm-Alvarez; J Andrew MacKay
Journal:  J Control Release       Date:  2014-12-03       Impact factor: 9.776

8.  Tissue transglutaminase is a negative regulator of monomeric lacritin bioactivity.

Authors:  Francisco Velez V; Jeffrey A Romano; Robert L McKown; Kari Green; Liwen Zhang; Ronald W Raab; Denise S Ryan; Cindy M L Hutnik; Henry F Frierson; Gordon W Laurie
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-01       Impact factor: 4.799

Review 9.  Molecular Functions of Glycoconjugates in Autophagy.

Authors:  Kamau Fahie; Natasha E Zachara
Journal:  J Mol Biol       Date:  2016-06-23       Impact factor: 5.469

10.  Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease.

Authors:  Trinka Vijmasi; Feeling Y T Chen; Suganthalakshmi Balasubbu; Marianne Gallup; Robert L McKown; Gordon W Laurie; Nancy A McNamara
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-07-17       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.